Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity

BJU International

Volumn 99, Issue 6, 2007, Pages 1433-1438

  Mansfield, Kylie J ^a,b   Liu, Lu ^b   Moore, Kate H ^c   Vaux, Kenneth J ^d   Millard, Richard J ^e   Burcher, Elizabeth ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d SYDNEY ADVENTIST HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Bladder; Muscarinic; Overactive bladder; Quantitative competitive RT PCR; Urothelium

Indexed keywords

BETA ACTIN; MESSENGER RNA; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; RNA; ACTIN; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BLADDER; BLADDER BIOPSY; BLADDER MUCOSA; CONTROLLED STUDY; CYSTOSCOPY; DETRUSOR MUSCLE; DISSECTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LAMINA PROPRIA; MOLECULAR BIOLOGY; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; URODYNAMICS; UROTHELIUM; BIOPSY; CASE CONTROL STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; MUCOSA; PATHOLOGY;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 34447325384     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06866.x     Document Type: Article

References (24)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6
2. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Invest Drugs 2004 13 : 1493 500
3. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype selective muscarinic receptor antagonists. Eur J Pharmacol 1998 394 : 285 92
4. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000 129 : 416 9
5. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005 144 : 1089 99
6. Tyagi S, Tyagi P, Van-Le S, Yoshimura N, Chancellor MB, de Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 2006 176 : 1673 8
7. Moore KH, Gilpin SA, Dixon JS, Richmond DH, Sutherst JR. Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor overactivity. Br J Urol 1992 70 : 370 2
8. Yoshida M, Inadome A, Maeda Y et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006 67 : 425 30
9. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autocoid Pharmacol 2002 22 : 133 45
10. Guerrero K, Emery S, Owen L, Rowlands M. Intravesical oxybutynin: practicalities of clinical use. J Obstet Gynaecol 2006 26 : 141 3
11. Chaiyaprasithi B, Mang CF, Kilbinger H, Hohenfellner M. Inhibition of human detrusor contraction by a urothelium derived factor. J Urol 2003 170 : 1897 900
12. Scott R, Chapple C, Chess-Williams R. Which muscarinic receptor subtype causes the release of the urothelium derived inhibitory factor in the female pig bladder. Eur Urol Suppl 2005 4 : 55 Abstract
13. Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006 176 : 367 73
14. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001 21 : 243 8
15. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002 136 : 641 3
16. Hinata N, Shirakawa T, Okada H, Achaya B, Kamidono S, Gotoh A. Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder. Mol Diagn 2004 8 : 17 22
17. Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle from stable, unstable and obstructed bladders. J Urol 1999 162 : 1833 9
18. Moore KH, Lam DS, Lynch W, Burcher E. The tachykinin NK-2 receptor antagonist SR48968 does not block noncholinergic contractions in unstable human bladder. Peptides 2002 23 : 1155 60
19. Sellers DJ, Chapple CR, Hay DP, Chess-Williams R. Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle. Eur Urol 2006 49 : 510 8
20. Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003 169 : 843 8
21. Booth CM, Whiteside CG, Turner-Warwick RT. A long-term study of the persistence of the urodynamic characteristics of the unstable bladder. Br J Urol 1981 53 : 310 4
22. Morris AR, Westbrook JI, Moore KH. Idiopathic detrusor overactivity in women - A 5-10 year longitudinal study of outcomes. Neurourol Urodyn 2003 22 : 460 2
23. Schurch B, de Sèze M, Denys P et al. Botulinum toxin A (Botox®) in neurogenic urinary incontinence: results from a multi centre randomized, controlled trial. Neurourol Urodyn 2004 23 : 609 10
24. Fowler CJ. Intravesical treatment of overactive bladder. Urology 2000 55 (Suppl. 60 4